Moreover, the addition of cytokines known to drive the alternative activation program in macrophages, i. e. recombinant IL-4 or IL-13 (S2A Fig), inhibited LBs accumulation in TB-PE-treated M0 in a dose-dependent manner (Fig 1B and 1C and S2B and S2C Fig). Here, IL13 is linked to tuberculosis.